To explore the role of TCIRG1 in renal cancer immunotherapy, we first analyzed the potential for immune escape among different TCIRG1 expression subgroups and found that the high-TCIRG1 expression group was responsive to immunotherapy and had a higher propensity for immune escape, which also indicated that patients with low TCIRG1 expression might be more likely to benefit from immunotherapy. The gene discussed is TCIRG1; the disease is renal carcinoma.